VYNE Therapeutics (VYNE)
(Real Time Quote from BATS)
$0.37 USD
+0.01 (1.37%)
Updated Aug 7, 2025 10:04 AM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VYNE 0.37 +0.01(1.37%)
Will VYNE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYNE
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Other News for VYNE
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
VYNE Therapeutics (VYNE) Downgraded by HC Wainwright & Co. | VYNE Stock News
VYNE Downgraded to Neutral by H.C. Wainwright Analyst
VYNE Therapeutics Downgraded After Phase 2b Trial Setback